In one paragraphArticle in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
14 authors.
Samuel OkurutResearch Department, Infectious Diseases Institute, Makerere University, Kampala, Uganda.ORCID 0000-0002-9292-8687 David R BoulwareDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-4715-0060 Yukari C ManabeResearch Department, Infectious Diseases Institute, Makerere University, Kampala, Uganda.ORCID 0000-0001-8619-5598 Lillian TugumeResearch Department, Infectious Diseases Institute, Makerere University, Kampala, Uganda.ORCID 0000-0002-1293-1545 Caleb P SkipperDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-0000-8876 Kenneth SsebambuliddeResearch Department, Infectious Diseases Institute, Makerere University, Kampala, Uganda.ORCID 0000-0002-8125-0698 Joshua RheinDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-0480-9646 Abdu K MusubireResearch Department, Infectious Diseases Institute, Makerere University, Kampala, Uganda.ORCID 0000-0003-2410-5344 Andrew AkampuriraResearch Department, Infectious Diseases Institute, Makerere University, Kampala, Uganda.
Elizabeth OkaforDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Joseph O OloboDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0001-5148-8876 Edward N JanoffMucosal and Vaccine Research Program Colorado, Department of Medicine, Division of Infectious Diseases, University of Colorado Denver, Aurora, Colorado, CO. USA.ORCID 0000-0003-2702-5729 David B MeyaResearch Department, Infectious Diseases Institute, Makerere University, Kampala, Uganda.ORCID 0000-0002-8854-0321 ASTRO Trial Team.
Funding
NPGH LEADERs YR12: OBSSR (Greenberg, Ngwafong Mukere) & NIBIB (Lee)D43TW009345 · FIC · UNIVERSITY OF WASHINGTON · PI Dibyadyuti Datta, Chandy C. John · 2017 to 2026
$15.2MImproving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related MeningitisR01NS086312 · NINDS · UNIVERSITY OF MINNESOTA · PI David R Boulware, David Bisagaya Meya · 2013 to 2026
$8.3MInfectious Disease Training in Clinical InvestigationT32AI055433 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI David R Boulware · 2003 to 2026
$6.1MNorthern/Pacific Universities Global Health Research Training ConsortiumR25TW009345 · FIC · UNIVERSITY OF WASHINGTON · PI KOLARS, JOSEPH C., NERURKAR, VIVEK RAMCHANDRA · 2012 to 2016
$5.9MTB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory TherapiesR01AI162786 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R, MEYA, DAVID BISAGAYA · 2021 to 2025
$3.3MHIV Co-infections in Uganda: TB, Cryptococcus, and Viral Hepatitis.D43TW009771 · FIC · JOHNS HOPKINS UNIVERSITY · PI CASTELNUOVO, BARBARA, KAMBUGU, ANDREW DDUNGU · 2014 to 2023
$3.3MMechanisms of Impaired HIV-associated B cell and Pneumococcal Vaccine responsesR01AI108479 · NIAID · UNIVERSITY OF COLORADO DENVER · PI JANOFF, EDWARD N · 2014 to 2018
$2.3MOutcomes of Cryptococcal Meningitis in UgandaK24AI096925 · NIAID · UNIVERSITY OF MINNESOTA · PI BOHJANEN, PAUL R · 2011 to 2015
$1.0MThe immunopathogenesis of HIV-related Immune Reconstitution Inflammatory SyndromeR01AI078934 · NIAID · INFECTIOUS DISEASES INSTITUTE · PI KAMBUGU, ANDREW DDUNGU, MEYA, DAVID BISAGAYA · 2010 to 2013
$415kImpact of HIV and HIV therapy on the Etiology and Outcome of Meningitis in UgandaR21NS065713 · NINDS · UNIVERSITY OF MINNESOTA · PI BOHJANEN, PAUL R, BOULWARE, DAVID R · 2010 to 2011
$276kImpact of HIV-1 and Aging on Mucosal Vaccine ResponsesI01CX001464 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI JANOFF, EDWARD N · 2017 to 2021
–CSRD VA I01 CX001464FIC NIH HHS D43 TW009345FIC NIH HHS D43 TW009771FIC NIH HHS R25 TW009345NIAID NIH HHS K24 AI096925NIAID NIH HHS R01 AI078934NIAID NIH HHS R01 AI108479NIAID NIH HHS R01 AI162786NIAID NIH HHS T32 AI055433NINDS NIH HHS R01 NS086312NINDS NIH HHS R21 NS065713Wellcome Trust
6 · The paper itselfAbstract
Introduction: Cryptococcal meningitis remains a prominent cause of death in persons with advanced HIV disease. CSF leukocyte infiltration predicts survival at 18 weeks; however, how CSF immune response relates to CSF leukocyte infiltration is unknown. Methods: We enrolled 401 adults with HIV-associated cryptococcal meningitis in Uganda who received amphotericin and fluconazole induction therapy. We assessed the association of CSF leukocytes, chemokine, and cytokine responses with 18-week survival. Results: Participants with CSF leukocytes ≥50/μL, had higher probability 68% (52/77) of 18-week survival compared with 52% (151/292) 18-week survival in those with ≤50 cells/μL (Hazard Ratio=1.63, 95% confidence intervals 1.14-2.23; p=0.008). Survival was also associated with higher expression of T helper (Th)-1, Th17 cytokines, and immune regulatory elements. CSF levels of Programmed Death-1 Ligand, CXCL10, and Interleukin (IL)-2 independently predicted survival. In multivariate analysis, CSF leukocytes were inversely associated with CSF fungal burden and positively associated with CSF protein, interferon-gamma (IFN-γ), IL-17A, tumor necrosis factor (TNF)-α, and peripheral blood CD4 Conclusion: 18-week survival after diagnosis of cryptococcal meningitis was associated with higher CSF leukocytes at baseline with greater T helper 1 (IFN-γ, IL-2 and TNF-α cytokines), T helper 17 (IL-17A cytokine) and CXCR3
Indexed as
antifungal therapycerebrospinal fluidchemokinesCSF white cellscytokinesfungal burdenHIV-associated cryptococcal meningitisimmune responsesurvival
Identifiers
PMID38854002
PMCPMC11160828
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390